News & Updates

Show Multimedia Only

Erlotinib lowers polyp burden in familial adenomatous polyposis

07 Jun 2022

Treatment with erlotinib is well tolerated and leads to a reduction in duodenal and lower gastrointestinal polyp burden in patients with familial adenomatous polyposis, according to data from a phase II trial.

07 Jun 2022

SPLENDID unmasks benefits of bariatric surgery in cancer

07 Jun 2022 by

New evidence from the SPLENDID study unmasks the benefits of weight loss achieved with bariatric surgery in protecting against cancer.

07 Jun 2022

Molecular stratification useful for fine prognostication of adult gliomas

07 Jun 2022 by

A study conducted by the Chinese University of Hong Kong (CUHK), Fudan University in Shanghai, China, and Zhengzhou University in Zhengzhou, China, has found that a molecular stratification system based on single-gene alterations aids fine prognostication of adult gliomas.

07 Jun 2022

High-frequency mutations seen in conjunctival melanoma

06 Jun 2022

Patients with conjunctival melanoma exhibit a high frequency of BRAF and NRAS mutations, as well as ATRX and NF1 mutations, reports a study.

06 Jun 2022

Iatrogenic tumour seeding not a risk factor for metachronous CRC

06 Jun 2022

In patients with colorectal cancer (CRC), biopsy of nontumour sites after biopsy of the primary cancer is unlikely to cause metachronous cancers, a study reports.

06 Jun 2022

Elacestrant ups PFS vs SoC ET in ER-positive, HER2-negative advanced breast cancer

06 Jun 2022 by

Elacestrant, a novel oral selective oestrogen receptor (ER) degrader, significantly improves progression-free survival (PFS) vs standard-of-care (SoC) endocrine therapy (ET) in patients with ER-positive, HER2-negative advanced breast cancer whose disease progressed after 1–2 prior lines of ET and a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, results of the phase III EMERALD trial have shown.

06 Jun 2022

Is proton treatment better than radiation therapy for anal cancer?

05 Jun 2022

Intensity modulated proton therapy (IMPT) leads to a reduction in bone marrow doses but not to a lower haematologic toxicity when compared to intensity modulated radiation therapy (IMRT) in patients with anal cancer, reveals a recent study.

05 Jun 2022

Brain metastasis, haemorrhage common in cardiac angiosarcoma, need early treatment

04 Jun 2022

Brain metastasis usually develops in patients with cardiac angiosarcoma (CA), and their risk of intracranial haemorrhage (IH) is high, results of a study have shown. This leads to an alarming rate of terminal haemorrhage (TH) despite normal platelet counts.

04 Jun 2022